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in peripheral �lood and �one marrow of some patients 
with non-Hodgkin’s lymphomas.
In �99�� the Reference La�oratory was set up as a pu�-
lic service on the �asis of the Immunocytochemistry 
�epartment of R.E. Kavetsky Institute of Experimental 
Pathology� Oncology and Radio�io logy� National Acad-
emy of Sciences of Ukraine with the aim of the precise 
diagnosis of the haematopoietic malignancies �ased 
on cytomorphology� cytoche mistry� immunophenotyping 
and the techniques of molecular �iology in accordance 
with FAB� WHO� EGIL� IC�-�� and IC�-O-� classifications. 
The diagnostic activity of the Reference La�oratory covers 
�5-�5% of all Ukrainian patients with acute leukemias� 
chronic lymphoid and myeloid leukemias� myelodysplastic 
syndromes� malignant lymphomas� histiocytosis� and 
metastatic lesions of lymph nodes and �one marrow. 
At present� the patients with tumors of haematopoietic and 
lymphoid tissues are diagnosed according to up-to-date 
WHO classification. We �elieve that only precise diagnosis 
of the major types of hematological malignancies to the 
up-to-date classification with delineation of the specific 
�iological su�types of hematological malignancies may 
represent the �asis for further molecular �iological and 
epidemiological studies. New insight into the �iology of the 
lymphoid malignancies in the coming years might well 
improve our a�ility to evaluate patients and chose therapy.
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Chronic lymphocytic leukemia �CLL� is the most com-
mon form of leukemia in Western countries with an inci-
dence of �.�/�������/year [�]. The incidence increases 
to >��/�������/year at an age of >�� years. The median 
age at diagnosis is �� years. A�out ��% of CLL patients 
are reported to �e younger than 55 years.
The guidelines for the diagnosis and treatment 
of chronic lymphocytic leukemia were revised �y the 
International Workshop on CLL in ���� �IWCLL�. Crite-
ria for CLL are as follows: the presence in the peripheral 
�lood of 5 x ��9/L monoclonal B lymphocytes for the 
at least � months. The clonality of the circulating B lym-
phocytes needs to �e confirmed �y flow cyto metry [�]. 
Typical immunophenotype of CLL lymphocyte is C�5+� 
C���+� C���+/-� C���-� C��9+� C��� dim� slgdim+ and 
cyclin �I� [�]. Bone marrow examination is not required 
for diagnosis and a CT scan not required for staging� 
�ut flow cytometry is crucial for correct diagnosis.
The first prognostic marker to �e used in the 
clinical management of CLL was the Rai clinical stag-
ing system� pu�lished in �9�5 [�]. This system was 
later followed �y the Binet staging system� pu�lished 
in �9�� [5]. Both of these staging systems provide 
a �asic framework for estimating prognosis and are 
factored into the current International Workshop 
on CLL guidelines for initiation of treatment [�].
Multiple factors� measured in standard clinical la�-
oratory tests� affect the clinical course of CLL. These 
factors include lymphocyte count� lymphocyte dou-
�ling time� M level� sTK level� angiopoietin-� �Ang-�� 
level� and solu�le cluster designation markers �C���� 
C���� and C��9d�. Other clinical markers that have 
�een investigated as potential prognostic indicators 
include age� gender [6]� lymphocyte dou�ling time [�]� 
num�er of prolymphocytes [�]� pattern of �one mar-
row involvement and percentage of smudge cells [9].
Approximately ��% of individuals with CLL have 
acquired chromosomal a�normalities within their 
malignant clone and can �e categorized into five 
prognostic groups accordingly: deletion ��q �median 
survival� ��� months�; deletion ��q �median survival� 
�9 months�; trisomy �� �median survival� ��� months�; 
normal cytogenetics �median survival� ��� months�; 
and deletion ��p �median survival� �� months�. Re-
ciprocal chromosome translocations are descri�ed 
�ut are rare in CLL. A complex cytogenetic karyotype 
can �e identified in ~I6% of patients and is commonly 
associated with poor prognostic features including 
C��� expression and unmutated IgHV [��].
The outcome of patients with leukemic cells that use 
an unmutated IgVH gene is inferior to those patients with 
leukemic cells that use a mutated IgVH gene. In addi-
tion� the VH�.�� gene usage is an unfavora�le prognos-
tic marker independent of the IgVH mutational status. 
Leukemic cell expression of ZAP-�� and C��� was 
found to correlate with the expression of unmutated 
IgVH genes and to predict a poor prognosis.
However� the association �etween expression of ZAP-
�� or C��� with the expression of unmutated IgVH genes 
is not a�solute. It is uncertain whether leukemia-cell 
expression of unmutated IgVH genes or ZAP-�� pre-
dict the response to treatment or overall survival� once 
therapy is required. Taken together� further clinical trials 
are needed to standardize the assessment of these pa-
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rameters and to determine whether they should affect 
the management of patients with CLL [�].
Recently 9 significantly mutated genes were identi-
fied that occurred in 5 core signaling pathways in which 
the genes play esta�lished roles: �NA damage repair 
and cell-cycle control �TP53, ATM�� Notch signaling 
�FBXW7, NOTCH I�� inflammatory pathways �MYD88, 
DDX3X, MAPKI�� and RNA splicing/processing �SF3BI, 
DDX3X�. Of these mutations� 5 of the mutated genes 
have �een implicated in CLL for the first time [��].
Treatment of CLL ranges from periodic o�servation 
with treatment of infectious� hemorrhagic� or immuno-
logic complications to a variety of therapeutic options� 
including steroids� alkylating agents� purine analogs� 
com�ination chemotherapy� monoclonal anti�odies� 
and transplant options [��]. A meta analysis of rando-
mized trials showed no survival �enefit for immediate 
versus delayed therapy for patients with early stage 
disease� nor for the use of com�ination regimens 
incorporating an anthracycline compared with a single-
agent alkylator for advanced stage disease.
Indication for start of treatment are as follows: Binet 
stage C� Rai stages III or IV� Binet stage B or Rai stages 
I or II� with at least one of: splenomegaly� and or lymph-
adenopathy� when symptomatic� progressive� or massive 
�> 5 cm spleen� �� cm nodes� progressive lymphocytosis 
�increase > 5�% in � months or Lymphocyte �ou�ling 
Time < 6 months� AIHA or ITP unresponsive to cortico-
steroids� disease-related symptom �i.e.� weight loss� 
significant fatigue� fever�. Biological markers �e.g. cyto-
genetics� C���� ZAP-��� IGVH mutations� are not an in-
dication to start therapy �outside clinical trials�. Response 
to therapy is the most important prognostic factor.
Recently su�stantial advances have �een made in the 
treatment of CLL patients� most of which relate to mono-
clonal anti�odies �MA�� alone and in com�ination with 
various chemotherapeutic drug com�inations. Preferred 
treatment of choice �for patients with good performance 
status� is the com�ination of rituxima� with fludara�ine 
and cyclophosphamide �R-FC�. Phase � clinical studies 
demonstrated that R-FC is the most effective com�ina-
tion to date in terms of achieving CR in CLL in previously 
untreated [��] and treated [��] patients.
Allogeneic stem cell transplant has �een found 
to induce long-term disease-free survival in CLL pa-
tients with deletion ��p [�5]. However� given the age 
of diagnosis and frequent presence of co-mor�idities� 
transplant is not often an option for these patients. This 
has led to a search for non-p5� dependent agents for 
use in the management of CLL with deletion ��p.
Alemtuzuma�� on the other hand� appears to work 
via a p5� independent pathway� and has demonstrated 
efficacy in ��p deleted or p5� mutated CLL [�6]. Less 
effective for �ulky �5 cm�. ��p- patients who present with 
�ulky lymphadenopathy remains a therapeutic challenge.
Ofatumuma�� a human C��� Ma� that �inds 
to another C��� epitope� has shown promising results 
when used as a single agent in refractory CLL patients 
OR rate of approx 5�% with a significantly longer sur-
vival in responding patients [��]. Several other MA�s 
are in early clinical testing or in the pipeline. In addi-
tion� a growing num�er of small molecules are �eing 
explored in clinical trials� providing hope for the future 
that CLL will �e transformed into a disease that may 
�e kept under control for very long periods of time.
For the selection of second-line treatment� the qual-
ity of first response plays a major role — if physically 
fit patients with refractory disease or relapse within 
�� months after chemoimmunotherapy — or fludara-
�ine-�ased com�ination therapy� the second remis-
sion should �e used to proceed to an allogeneic stem 
cell transplant �especially indicated in very high risk 
[del�l�p�� p5� mutation] and/or refractory disease [��].
If the patient is physically unfit� the treatment 
should �e changed to an alternative regimen. The 
prognosis in this group is usually poor. If relapse is later 
than �� months after the first therapy� the first-line 
therapy should �e repeated.
O�limersen is a drug that has �een studied for use 
in CLL. An immunotoxin known as BL�� has shown 
a great deal of promise in treating hairy cell leukemia 
�HCL� in clinical trials. A newer version of this drug� known 
as HA�� �CAT-���5� is now �eing tested for use against 
CLL. The Bruton’s tyrosine kinase �BTK� inhi�itor PCI 
���65 �under development �y Pharmacyclics� showed 
high rates of progression-free survival and low toxicity 
in patients with relapsed CLL� according to data presented 
here at American Society of Hematology �ASH� 5�rd An-
nual Meeting. The drug is now in a phase � clinical trial.
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Follicular lymphoma �FL� is the second most com-
mon type of non-Hodgkin lymphoma �NHL� in Western 
Countries� accounting for ��% of all NHL and for ��% 
of all indolent forms� with a median age at diagnosis 
of a�out 6� years [���]. Before the advent of chemo-
therapy� the majority of patients with FL died within 
5 years. With the current therapies� the expected me-
dian survival is approximately ���� years [�]. A�out �5% 
of FL cases have a specific translocation t���;��� that 
leads to the overexpression of the BCL� protein� a mem-
�er of a family of anti-apoptotic proteins� although other 
genetic alterations may �e detected in this su�type 
of lymphoma. As defined �y the WHO� FLs are charac-
terized �y a follicular growth pattern including centro-
cytes �small- to medium-sized cells� and centro�lasts 
�large cells�� and are graded from I to III according to the 
amount of centro�lasts present. The clinical aggressive-
ness of the tumor increases with an increasing num�ers 
of centro�lasts. Grade I is defined �y ≥5 centro�lasts/
high power field �hpf� �follicular small cleaved�� Grade 
II �y 6 to �5 centro�lasts/hpf �follicular mixed�� Grade III 
�y more than �5 centro�lasts/hpf �follicular large cell�. 
Grade III has �een su�divided into Grade IIIa� in which 
centrocytes are present and Grade III�� in which there 
are sheets of centro�lasts. Grade from I to IIIa are 
considered as indolent NHL su�types� while grade III� 
�ehaves as an aggressive lymphoma and is treated 
similarly to a diffuse large B-cell lymphoma [5]. Bone 
marrow involvement is very common �a�out ��% of all 
cases� with paratra�ecular lymphoid aggregates� al-
though other organ involvement is uncommon. FL cells 
express monoclonal immunoglo�ulin �Ig� light chains; 
they are C��9+� C���+� C���+� C���+ and BCL�+� while 
they are negative for C�5 and C���. Clonal Ig gene 
rearrangements are also present and most cases have 
extensive somatic mutations.
In recent decades� the introduction of several treat-
ment options �single alkylating agents� com�ination 
chemotherapy with or without doxoru�icin or fludara�ine� 
total lymphoid irradiation� has improved the overall survival 
�OS� for patients with FL� with complete remission rates 
ranging from 65 to �5% [6]. Fisher et al. demonstrated that 
the introduction of the anti-C��� monoclonal anti�ody 
Rituxima� significantly improved OS [�]. The prognosis 
of FL at diagnosis is currently evaluated on the �asis 
of specific indexes: the Follicular Lymphoma International 
Prognostic Index �FLIPI� considers five prognostic factors� 
including patient age� stage� num�er of involved nodal ar-
eas� serum lactate dehydrogenase and hemoglo�in level 
[�]. It was developed through an international retrospec-
tive study of survival data on ��6� patients with FL diag-
nosed �etween �9�5 and �99�. Currently� FLIPI is a widely 
accepted tool for risk assessment of FL. However� the FLIPI 
has �een designed prior to the era of anti-C��� monoclo-
nal anti�odies and the initial cohort does not represent the 
present course of the disease. More recently� a modified 
version of this scoring system� the FLIPI-�� was proposed 
�y Federico et al. [9] on the �asis of the F� study� in which 
��9� patients �etween January ���� and May ���5 with 
a newly diagnosed FL were registered and 9�� individuals 
receiving treatment were selected as the study popula-
tion. This new prognostic score has� as a target end point� 
progression-free survival �PFS�� considered more realistic 
than OS for a type of lymphoma with a median survival 
likelihood of �� years.
Treatment options are stage-related: while dis-
seminated FL is considered an incura�le disease� with 
a trend to relapse� localized stage FL potentially has 
a different clinical outcome. In fact� it has �een dem-
onstrated that in 5�% of cases it is possi�le to o�tain 
a definitive eradication of the disease. According to the 
current guidelines [��� ��]� stage I�II disease should not 
�e managed with a frontline strategy of watchful waiting� 
radiation therapy representing the gold standard for this 
group of patients: a radiation dose of �� to �6 Gy deliv-
ered in �5 to �� fractions over ��� weeks is associated 
with local control rates of more than 95%. �espite the 
limited stage� BCL2/IgH+ positive cells could �e found 
at diagnosis in the peripheral �lood and/or �one marrow 
of �6 of �� patients �66.6%� �y quantitative PCR and 
